Global And United States Neurodegenerative Disease Market Size, Status And Forecast 2021-2027

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 ParkinsonÕs Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 AlzheimerÕs Disease
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neurodegenerative Disease Market Perspective (2016-2027)
2.2 Neurodegenerative Disease Growth Trends by Regions
2.2.1 Neurodegenerative Disease Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurodegenerative Disease Historic Market Share by Regions (2016-2021)
2.2.3 Neurodegenerative Disease Forecasted Market Size by Regions (2022-2027)
2.3 Neurodegenerative Disease Industry Dynamic
2.3.1 Neurodegenerative Disease Market Trends
2.3.2 Neurodegenerative Disease Market Drivers
2.3.3 Neurodegenerative Disease Market Challenges
2.3.4 Neurodegenerative Disease Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease Players by Revenue
3.1.1 Global Top Neurodegenerative Disease Players by Revenue (2016-2021)
3.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2016-2021)
3.2 Global Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disease Revenue
3.4 Global Neurodegenerative Disease Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Revenue in 2020
3.5 Neurodegenerative Disease Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disease Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disease Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disease Breakdown Data by Type
4.1 Global Neurodegenerative Disease Historic Market Size by Type (2016-2021)
4.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2022-2027)

5 Neurodegenerative Disease Breakdown Data by Application
5.1 Global Neurodegenerative Disease Historic Market Size by Application (2016-2021)
5.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neurodegenerative Disease Market Size (2016-2027)
6.2 North America Neurodegenerative Disease Market Size by Type
6.2.1 North America Neurodegenerative Disease Market Size by Type (2016-2021)
6.2.2 North America Neurodegenerative Disease Market Size by Type (2022-2027)
6.2.3 North America Neurodegenerative Disease Market Size by Type (2016-2027)
6.3 North America Neurodegenerative Disease Market Size by Application
6.3.1 North America Neurodegenerative Disease Market Size by Application (2016-2021)
6.3.2 North America Neurodegenerative Disease Market Size by Application (2022-2027)
6.3.3 North America Neurodegenerative Disease Market Size by Application (2016-2027)
6.4 North America Neurodegenerative Disease Market Size by Country
6.4.1 North America Neurodegenerative Disease Market Size by Country (2016-2021)
6.4.2 North America Neurodegenerative Disease Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neurodegenerative Disease Market Size (2016-2027)
7.2 Europe Neurodegenerative Disease Market Size by Type
7.2.1 Europe Neurodegenerative Disease Market Size by Type (2016-2021)
7.2.2 Europe Neurodegenerative Disease Market Size by Type (2022-2027)
7.2.3 Europe Neurodegenerative Disease Market Size by Type (2016-2027)
7.3 Europe Neurodegenerative Disease Market Size by Application
7.3.1 Europe Neurodegenerative Disease Market Size by Application (2016-2021)
7.3.2 Europe Neurodegenerative Disease Market Size by Application (2022-2027)
7.3.3 Europe Neurodegenerative Disease Market Size by Application (2016-2027)
7.4 Europe Neurodegenerative Disease Market Size by Country
7.4.1 Europe Neurodegenerative Disease Market Size by Country (2016-2021)
7.4.2 Europe Neurodegenerative Disease Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Market Size (2016-2027)
8.2 Asia-Pacific Neurodegenerative Disease Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurodegenerative Disease Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurodegenerative Disease Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurodegenerative Disease Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurodegenerative Disease Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Disease Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurodegenerative Disease Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neurodegenerative Disease Market Size (2016-2027)
9.2 Latin America Neurodegenerative Disease Market Size by Type
9.2.1 Latin America Neurodegenerative Disease Market Size by Type (2016-2021)
9.2.2 Latin America Neurodegenerative Disease Market Size by Type (2022-2027)
9.2.3 Latin America Neurodegenerative Disease Market Size by Type (2016-2027)
9.3 Latin America Neurodegenerative Disease Market Size by Application
9.3.1 Latin America Neurodegenerative Disease Market Size by Application (2016-2021)
9.3.2 Latin America Neurodegenerative Disease Market Size by Application (2022-2027)
9.3.3 Latin America Neurodegenerative Disease Market Size by Application (2016-2027)
9.4 Latin America Neurodegenerative Disease Market Size by Country
9.4.1 Latin America Neurodegenerative Disease Market Size by Country (2016-2021)
9.4.2 Latin America Neurodegenerative Disease Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Market Size (2016-2027)
10.2 Middle East & Africa Neurodegenerative Disease Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurodegenerative Disease Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurodegenerative Disease Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurodegenerative Disease Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurodegenerative Disease Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Disease Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurodegenerative Disease Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Neurodegenerative Disease Introduction
11.1.4 Novartis Revenue in Neurodegenerative Disease Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Disease Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Disease Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Merck Serono
11.3.1 Merck Serono Company Details
11.3.2 Merck Serono Business Overview
11.3.3 Merck Serono Neurodegenerative Disease Introduction
11.3.4 Merck Serono Revenue in Neurodegenerative Disease Business (2016-2021)
11.3.5 Merck Serono Recent Development
11.4 Biogen Idec
11.4.1 Biogen Idec Company Details
11.4.2 Biogen Idec Business Overview
11.4.3 Biogen Idec Neurodegenerative Disease Introduction
11.4.4 Biogen Idec Revenue in Neurodegenerative Disease Business (2016-2021)
11.4.5 Biogen Idec Recent Development
11.5 TEVA
11.5.1 TEVA Company Details
11.5.2 TEVA Business Overview
11.5.3 TEVA Neurodegenerative Disease Introduction
11.5.4 TEVA Revenue in Neurodegenerative Disease Business (2016-2021)
11.5.5 TEVA Recent Development
11.6 UCB
11.6.1 UCB Company Details
11.6.2 UCB Business Overview
11.6.3 UCB Neurodegenerative Disease Introduction
11.6.4 UCB Revenue in Neurodegenerative Disease Business (2016-2021)
11.6.5 UCB Recent Development
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Details
11.7.2 Boehringer Ingelheim Business Overview
11.7.3 Boehringer Ingelheim Neurodegenerative Disease Introduction
11.7.4 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2016-2021)
11.7.5 Boehringer Ingelheim Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Neurodegenerative Disease Introduction
11.8.4 Sanofi Revenue in Neurodegenerative Disease Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Neurodegenerative Disease Introduction
11.9.4 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2016-2021)
11.9.5 GlaxoSmithKline Recent Development
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Details
11.10.2 Livzon Pharmaceutical Business Overview
11.10.3 Livzon Pharmaceutical Neurodegenerative Disease Introduction
11.10.4 Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.10.5 Livzon Pharmaceutical Recent Development
11.11 Haisco Pharmaceutical
11.11.1 Haisco Pharmaceutical Company Details
11.11.2 Haisco Pharmaceutical Business Overview
11.11.3 Haisco Pharmaceutical Neurodegenerative Disease Introduction
11.11.4 Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.11.5 Haisco Pharmaceutical Recent Development
11.12 Jingxin Pharmaceutical
11.12.1 Jingxin Pharmaceutical Company Details
11.12.2 Jingxin Pharmaceutical Business Overview
11.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Introduction
11.12.4 Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.12.5 Jingxin Pharmaceutical Recent Development
11.13 Dongcheng Biochemicals
11.13.1 Dongcheng Biochemicals Company Details
11.13.2 Dongcheng Biochemicals Business Overview
11.13.3 Dongcheng Biochemicals Neurodegenerative Disease Introduction
11.13.4 Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2016-2021)
11.13.5 Dongcheng Biochemicals Recent Development
11.14 Hisun Pharmaceutical
11.14.1 Hisun Pharmaceutical Company Details
11.14.2 Hisun Pharmaceutical Business Overview
11.14.3 Hisun Pharmaceutical Neurodegenerative Disease Introduction
11.14.4 Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.14.5 Hisun Pharmaceutical Recent Development
11.15 Luye Pharma
11.15.1 Luye Pharma Company Details
11.15.2 Luye Pharma Business Overview
11.15.3 Luye Pharma Neurodegenerative Disease Introduction
11.15.4 Luye Pharma Revenue in Neurodegenerative Disease Business (2016-2021)
11.15.5 Luye Pharma Recent Development
11.16 Ark Pharmaceutical
11.16.1 Ark Pharmaceutical Company Details
11.16.2 Ark Pharmaceutical Business Overview
11.16.3 Ark Pharmaceutical Neurodegenerative Disease Introduction
11.16.4 Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.16.5 Ark Pharmaceutical Recent Development
11.17 Kanghong Pharmaceutical
11.17.1 Kanghong Pharmaceutical Company Details
11.17.2 Kanghong Pharmaceutical Business Overview
11.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Introduction
11.17.4 Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.17.5 Kanghong Pharmaceutical Recent Development
11.18 Huahai Pharmaceutical
11.18.1 Huahai Pharmaceutical Company Details
11.18.2 Huahai Pharmaceutical Business Overview
11.18.3 Huahai Pharmaceutical Neurodegenerative Disease Introduction
11.18.4 Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.18.5 Huahai Pharmaceutical Recent Development
11.18 BORA PHARMACEUTICALS
.1 BORA PHARMACEUTICALS Company Details
.2 BORA PHARMACEUTICALS Business Overview
.3 BORA PHARMACEUTICALS Neurodegenerative Disease Introduction
.4 BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2016-2021)
.5 BORA PHARMACEUTICALS Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of NMDA
Table 3. Key Players of SSRIs
Table 4. Key Players of Dopamine Inhibitors
Table 5. Global Neurodegenerative Disease Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neurodegenerative Disease Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neurodegenerative Disease Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Neurodegenerative Disease Market Share by Regions (2016-2021)
Table 9. Global Neurodegenerative Disease Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Neurodegenerative Disease Market Share by Regions (2022-2027)
Table 11. Neurodegenerative Disease Market Trends
Table 12. Neurodegenerative Disease Market Drivers
Table 13. Neurodegenerative Disease Market Challenges
Table 14. Neurodegenerative Disease Market Restraints
Table 15. Global Neurodegenerative Disease Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Neurodegenerative Disease Market Share by Players (2016-2021)
Table 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disease as of 2020)
Table 18. Ranking of Global Top Neurodegenerative Disease Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Neurodegenerative Disease Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neurodegenerative Disease Product Solution and Service
Table 22. Date of Enter into Neurodegenerative Disease Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Neurodegenerative Disease Revenue Market Share by Type (2016-2021)
Table 26. Global Neurodegenerative Disease Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Neurodegenerative Disease Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Neurodegenerative Disease Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Neurodegenerative Disease Revenue Market Share by Application (2016-2021)
Table 30. Global Neurodegenerative Disease Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Neurodegenerative Disease Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neurodegenerative Disease Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Neurodegenerative Disease Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
Table 62. Novartis Company Details
Table 63. Novartis Business Overview
Table 64. Novartis Neurodegenerative Disease Product
Table 65. Novartis Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 66. Novartis Recent Development
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer Neurodegenerative Disease Product
Table 70. Pfizer Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Merck Serono Company Details
Table 73. Merck Serono Business Overview
Table 74. Merck Serono Neurodegenerative Disease Product
Table 75. Merck Serono Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 76. Merck Serono Recent Development
Table 77. Biogen Idec Company Details
Table 78. Biogen Idec Business Overview
Table 79. Biogen Idec Neurodegenerative Disease Product
Table 80. Biogen Idec Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 81. Biogen Idec Recent Development
Table 82. TEVA Company Details
Table 83. TEVA Business Overview
Table 84. TEVA Neurodegenerative Disease Product
Table 85. TEVA Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 86. TEVA Recent Development
Table 87. UCB Company Details
Table 88. UCB Business Overview
Table 89. UCB Neurodegenerative Disease Product
Table 90. UCB Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 91. UCB Recent Development
Table 92. Boehringer Ingelheim Company Details
Table 93. Boehringer Ingelheim Business Overview
Table 94. Boehringer Ingelheim Neurodegenerative Disease Product
Table 95. Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 96. Boehringer Ingelheim Recent Development
Table 97. Sanofi Company Details
Table 98. Sanofi Business Overview
Table 99. Sanofi Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 100. Sanofi Recent Development
Table 101. GlaxoSmithKline Company Details
Table 102. GlaxoSmithKline Business Overview
Table 103. GlaxoSmithKline Neurodegenerative Disease Product
Table 104. GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 105. GlaxoSmithKline Recent Development
Table 106. Livzon Pharmaceutical Company Details
Table 107. Livzon Pharmaceutical Business Overview
Table 108. Livzon Pharmaceutical Neurodegenerative Disease Product
Table 109. Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 110. Livzon Pharmaceutical Recent Development
Table 111. Haisco Pharmaceutical Company Details
Table 112. Haisco Pharmaceutical Business Overview
Table 113. Haisco Pharmaceutical Neurodegenerative Disease Product
Table 114. Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 115. Haisco Pharmaceutical Recent Development
Table 116. Jingxin Pharmaceutical Company Details
Table 117. Jingxin Pharmaceutical Business Overview
Table 118. Jingxin Pharmaceutical Neurodegenerative Disease Product
Table 119. Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 120. Jingxin Pharmaceutical Recent Development
Table 121. Dongcheng Biochemicals Company Details
Table 122. Dongcheng Biochemicals Business Overview
Table 123. Dongcheng Biochemicals Neurodegenerative Disease Product
Table 124. Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 125. Dongcheng Biochemicals Recent Development
Table 126. Hisun Pharmaceutical Company Details
Table 127. Hisun Pharmaceutical Business Overview
Table 128. Hisun Pharmaceutical Neurodegenerative Disease Product
Table 129. Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 130. Hisun Pharmaceutical Recent Development
Table 131. Luye Pharma Company Details
Table 132. Luye Pharma Business Overview
Table 133. Luye Pharma Neurodegenerative Disease Product
Table 134. Luye Pharma Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 135. Luye Pharma Recent Development
Table 136. Ark Pharmaceutical Company Details
Table 137. Ark Pharmaceutical Business Overview
Table 138. Ark Pharmaceutical Neurodegenerative Disease Product
Table 139. Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 140. Ark Pharmaceutical Recent Development
Table 141. Kanghong Pharmaceutical Company Details
Table 142. Kanghong Pharmaceutical Business Overview
Table 143. Kanghong Pharmaceutical Neurodegenerative Disease Product
Table 144. Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 145. Kanghong Pharmaceutical Recent Development
Table 146. Huahai Pharmaceutical Company Details
Table 147. Huahai Pharmaceutical Business Overview
Table 148. Huahai Pharmaceutical Neurodegenerative Disease Product
Table 149. Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 150. Huahai Pharmaceutical Recent Development
Table 151. BORA PHARMACEUTICALS Company Details
Table 152. BORA PHARMACEUTICALS Business Overview
Table 153. BORA PHARMACEUTICALS Neurodegenerative Disease Product
Table 154. BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
Table 155. BORA PHARMACEUTICALS Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disease Market Share by Type: 2020 VS 2027
Figure 2. NMDA Features
Figure 3. SSRIs Features
Figure 4. Dopamine Inhibitors Features
Figure 5. Global Neurodegenerative Disease Market Share by Application: 2020 VS 2027
Figure 6. ParkinsonÕs Disease Case Studies
Figure 7. Huntington Disease Case Studies
Figure 8. Amyotrophic Lateral Sclerosis Case Studies
Figure 9. AlzheimerÕs Disease Case Studies
Figure 10. Neurodegenerative Disease Report Years Considered
Figure 11. Global Neurodegenerative Disease Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Neurodegenerative Disease Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Neurodegenerative Disease Market Share by Regions: 2020 VS 2027
Figure 14. Global Neurodegenerative Disease Market Share by Regions (2022-2027)
Figure 15. Global Neurodegenerative Disease Market Share by Players in 2020
Figure 16. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disease as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Revenue in 2020
Figure 18. Global Neurodegenerative Disease Revenue Market Share by Type (2016-2021)
Figure 19. Global Neurodegenerative Disease Revenue Market Share by Type (2022-2027)
Figure 20. North America Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 22. North America Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 23. North America Neurodegenerative Disease Market Share by Country (2016-2027)
Figure 24. United States Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 28. Europe Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 29. Europe Neurodegenerative Disease Market Share by Country (2016-2027)
Figure 30. Germany Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Neurodegenerative Disease Market Share by Region (2016-2027)
Figure 40. China Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 48. Latin America Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 49. Latin America Neurodegenerative Disease Market Share by Country (2016-2027)
Figure 50. Mexico Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neurodegenerative Disease Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Neurodegenerative Disease Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Neurodegenerative Disease Market Share by Country (2016-2027)
Figure 56. Turkey Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 61. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 62. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 63. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 64. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 65. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 66. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 67. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 68. Livzon Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 69. Haisco Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 70. Jingxin Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 71. Dongcheng Biochemicals Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 72. Hisun Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 73. Luye Pharma Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 74. Ark Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 75. Kanghong Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 76. Huahai Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 77. BORA PHARMACEUTICALS Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.